Anti-Human CD70 (CD27L) (Clone CPTC-CD70-1) – Purified No Carrier Protein

Synthetic peptide LYWQGGPALGR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI139R-2E11 activity is directed against human CD70 peptide sequence LYWQGGPALGR.

CPTC-CD70-1

CD70, also known as TNFSF7, is a type II transmembrane protein that is a member of the TNF receptor family¹. CD70, when bound to its ligand CD27, plays a role in B and T lymphocyte proliferation, B cell differentiation and activation, plasma cell differentiation, and germinal center formation. Additionally, CD4+ and CD8+ T cells proliferate and produce cytokines. CD70 overexpression can cause overstimulation of the CD70/CD27 axis, leading to T cell exhaustion and increased growth signaling to tumor cells. CD70 is overexpressed in a variety of solid and liquid tumors as well as B cell malignancies. Due to its role in tumor progression, CD70 is a target for immunotherapy in cancer^1,2.

FSAI139R-2E11 was generated in mouse for use in immuno-MRM assays using a synthetic peptide derived from human CD70, LYWQGGPALGR³. FSAI139R-2E11 detects CD70 in the NCI60 protein array and in cell lysates of some cell lines by Western blotting (A549, HeLa, and MCF7)⁴. FSAI139R-2E11 does not detect CD70 in immunohistochemistry, nor does it detect CD70 recombinant protein by Western blotting.

CD70 is expressed on highly activated B and T lymphocytes, mature dendritic cells, natural killer cells, and antigen-presenting cells in the intestinal mucosa. Expression is limited in normal tissues, with increased or atypical expression observed in many cancers.

CD27 receptor

1 Rav E, Maegawa S, Gopalakrishnan V, et al. J Immunol. 211(7):1067-1072. 2023.
2 Adam PJ, Terrett JA, Steers G, et al. Br J Cancer. 95(3):298-306. 2006.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-CD70+Peptide+1